Heterologous ChAdOx1-nCoV19-BNT162b2 vaccination provides superior immunogenicity against COVID-19

MLA

Christopher D. Richardson. “Heterologous ChAdOx1-NCoV19-BNT162b2 Vaccination Provides Superior Immunogenicity against COVID-19.” The Lancet. Respiratory Medicine, vol. 9, no. 11, July 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....f26bb286ef9b8fe9bdd2c4428f76c382&authtype=sso&custid=ns315887.

APA

Christopher D. Richardson. (2021). Heterologous ChAdOx1-nCoV19-BNT162b2 vaccination provides superior immunogenicity against COVID-19. The Lancet. Respiratory Medicine, 9(11).

Chicago

Christopher D. Richardson. 2021. “Heterologous ChAdOx1-NCoV19-BNT162b2 Vaccination Provides Superior Immunogenicity against COVID-19.” The Lancet. Respiratory Medicine 9 (11). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....f26bb286ef9b8fe9bdd2c4428f76c382&authtype=sso&custid=ns315887.